CLSA Applauds Governor Brown for Signing SB 212, Legislation to Establish a Statewide Drugs and Sharps Take-Back Program

Sacramento, CA – October 2, 2018California Life Sciences Association (CLSA), the trade association representing California’s life sciences industry, today applauded Gov. Jerry Brown for signing Senate Bill 212, legislation to establish a statewide drugs and sharps take-back program. SB 212 was approved by the California Legislature earlier this year and signed Sept. 30, by Brown. The following statement can be attributed to Sara Radcliffe, President & CEO, CLSA:

“On behalf of California’s life sciences innovators, a sector with over 3,000 firms employing 300,000 people, California Life Sciences Association (CLSA) applauds Governor Jerry Brown for signing Senate Bill 212, legislation that will help establish a statewide drugs and sharps take-back collection program for unused prescriptions, discarded needles and other medical waste.

“SB 212 represents a hard-negotiated compromise among numerous stakeholders that haven’t always seen eye-to-eye on the matter. CLSA has always worked to reach a consensus on finding a workable, statewide solution that puts patients first. As compromises often work, nobody got everything they wanted, but the alternative to this bill is something nearly all stakeholders involved wanted to avoid: years of a growing patchwork of local take-back programs potentially differing across as many as 58 counties and even more cities. We thank Governor Brown for signing SB 212 into law.”

Click here to learn more about the bill.


  • Learn more about the California life sciences industry
  • View CLSA’s Legislative Action Center
  • Watch CLSA’s Faces of California Biomedical Innovation Web Series
  • View CLSA’s Advocacy Priorities
  • View upcoming CLSA events

About California Life Sciences Association (CLSA)

California Life Sciences Association (CLSA) is the state’s largest and most influential life sciences advocacy and business leadership organization. With offices in Sacramento, San Diego, South San Francisco, Los Angeles and Washington DC, CLSA works closely with industry, government, academia and others to shape public policy, improve access to innovative technologies and grow California’s life sciences economy. CLSA serves biotechnology, pharmaceutical, medical device and diagnostics companies, research universities and institutes, investors and service providers throughout the Golden State. CLSA was founded in 2015 when the Bay Area Bioscience Association (BayBio) and the California Healthcare Institute (CHI) merged. Visit CLSA at, and follow us on Twitter @CALifeSciences, Facebook, Instagram, LinkedIn andYouTube.

Media Contact:
California Life Sciences Association (CLSA)
Will Zasadny | Director, Communications | 619-961-8848